KardiaAI

KardiaAI is a software analysis library designed for integration into ambulatory ECG devices, utilizing an API to provide algorithmic analysis of adult ECG rhythms. Its science involves ECG signal processing for noise filtering, heart rate calculation, and the automated detection of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia, validated through non-clinical performance testing.

KardiaAI is a Software as a Medical Device (SaMD) developed by AliveCor, Inc., functioning as a software analysis library. It is designed to be integrated into other ambulatory ECG device software via an Application Program Interface (API) to process and analyze 30-second electrocardiogram (ECG) rhythms from adult subjects. The core purpose of KardiaAI is to compute various physiologic parameters from ECGs, providing capabilities such as ECG noise filtering, heart rate measurement, detection of noisy ECGs, and ECG rhythm analysis. It is specifically intended for use with compatible event recorders or similar ambulatory ECG devices and is not designed for life-supporting systems, ECG monitors, cardiac alarms, or over-the-counter (OTC) use only devices. The KardiaAI library's analytical capabilities extend to detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia, with these rhythm analyses intended for use when prescribed or under the care of a physician. The algorithms for atrial fibrillation, normal sinus rhythm, and noise detection are shared with a predicate device, the Kardia Band System, while KardiaAI introduces additional classifiers for bradycardia and tachycardia. Non-clinical performance testing, utilizing ECG databases from the ANSI/AAMI EC57:2012 standard and proprietary AliveCor databases, was conducted to verify that the device performs as intended. This testing demonstrated that KardiaAI meets its specifications and its performance, including the newer algorithms and multi-lead ambulatory ECG input capability, is substantially equivalent to predicate devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific performance metrics (e.g., sensitivity, specificity, accuracy) of the KardiaAI algorithms for detecting atrial fibrillation, bradycardia, and tachycardia across diverse adult patient populations with varying comorbidities?; How does the KardiaAI's noise filtering algorithm differentiate between true physiological artifact and subtle pathological ECG changes, and what is its impact on diagnostic accuracy?; What are the technical integration requirements and potential compatibility challenges when incorporating the KardiaAI API library into different third-party ambulatory ECG hardware and software platforms?; How does the KardiaAI handle ECG recordings of durations significantly different from the 30-second standard, and what is the performance degradation, if any, for shorter or longer recordings?; What validation was performed to ensure the KardiaAI's algorithms are robust and maintain performance across different ECG signal qualities, lead configurations (beyond Lead I if applicable for multi-lead input), and patient-specific morphologies encountered from various compatible ambulatory ECG devices?